- Home
- / Amarin
Amarin
Stock Price
$0.6
2024-10-29
Market Capitalization
$257.6 M
2024-10-29
Revenue
$213.6 M
FY, 2025
Amarin Summary
Company Summary
- Overview
- Amarin Corporation is a pharmaceutical company that engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases. It develops VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia.
- Type
- Public
- Status
- Active
- Founded
- 1991
- HQ
- Dublin, IE | view all locations
- Website
- https://amarincorp.com/
- Cybersecurity rating
- ESG rating
Table of Contents
Key People
Jan van Heek, Non-Executive Director
Patrick J. O'Sullivan, Non-Executive Director
Kristine Peterson, Non-Executive Director
Operating MetricsView all
Patents (US)
110
19.6%
FY, 2020
Patent Applications (US)
30
FY, 2020
LocationsView all
3 locations detected
Dublin, D HQ
Ireland
Block C, 77 Sir John Rogerson's Quay
Bridgewater Township, NJ
United States
440 Route 22
Zug, ZG
Switzerland
Grafenauweg 8
Amarin Financials
Summary Financials
- Revenue (Q1, 2026)
- $45.1M
- Gross profit (Q1, 2026)
- $17.8M
- Net income (Q1, 2026)
- ($10.5M)
- Cash (Q1, 2026)
- $131.1M
- EBIT (Q1, 2026)
- ($11.3M)
- Enterprise value
- $132.1M